Cerebral Cavernous Malformations clinical trials at UCLA
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in subjects with symptomatic cerebral cavernous malformation (CCM).
Los Angeles, California and other locations